<DOC>
	<DOCNO>NCT01163292</DOCNO>
	<brief_summary>The present survey conduct evaluate effectiveness safety treatment adalimumab 52-week period follow completion treatment period Study NCT00870467 ( M06-859 ) participant continue treatment adalimumab 52 week .</brief_summary>
	<brief_title>Special Investigation ( Follow Survey Study Adalimumab ( D2E7 ) Prevention Joint Destruction Patients With Rheumatoid Arthritis Japan ( M06-859 ( NCT00870467 )</brief_title>
	<detailed_description>This survey conduct assess risk benefit continue discontinue biological therapy adalimumab ( Humira ) 52-week period follow completion treatment period Study NCT00870467 ( M06-859 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>The participant patient continue treatment adalimumab end treatment period NCT00870467 ( M06859 ) study provide informed consent participate present followup survey . Participants use biological agent adalimumab period treatment NCT00870467 ( M06859 ) study exclude present followup study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>